Genome Therapeutics Corp

Alkermes is a worldwide pharmaceutical company that develops controlled, sustained-release injectable drugs using with its trademark ProLease and Medisorb technologies. Located in Massachusetts, the company also develops inhaled formulations from its proprietary pulmonary technology. Alkermes has partnered with Johnson & Johnson to develop Riserpdal Consta, an antipsychotic drug used in the treatment of schizophrenia. Risperdal Consta is approved for sale in more than 50 countries that include the United States, United Kingdom and Germany. In addition to a host of partnered products, the ocmpany is also active in the development of several promising proprietary products, such as Vivitrex, a long-acting injectable form of naltrexone for alcohol dependence. Alkermes is headquartered in Cambridge, Mass.

Rana Therapeutics is a Cambridge-based company that focuses on disease areas, science technology, partnering, sustainable business, and careers. They offer a range of products and services for patients, healthcare professionals, and investors, and are committed to making a positive impact in the healthcare industry. With a strong emphasis on research and development, Rana Therapeutics aims to provide innovative solutions for various diseases. They prioritize accountability and transparency, as evidenced by their financial results, stock information, and press releases. As a reputable company, Rana Therapeutics is dedicated to improving patient outcomes and fostering partnerships within the healthcare community.Generated from the website

Whitehead Institute for Biomedical Research, located in Cambridge, MA, is a renowned non-profit research institution dedicated to advancing human health through fundamental biomedical research. With a focus on foundational science, their team of world-class researchers and scientists strive to unravel the mysteries of biology and uncover the mechanisms underlying various diseases. Through their groundbreaking discoveries, Whitehead Institute aims to pave the way for new approaches in medicine and contribute to the development of innovative therapies and treatments. Since its establishment in 1982, Whitehead Institute has been at the forefront of scientific exploration, continuously pushing the boundaries of knowledge in the biomedical field. With access to cutting-edge research tools and a deep commitment to understanding biological systems, their researchers are uniquely positioned to make significant contributions to the advancement of basic science. By delving into the core questions of biology, Whitehead Institute plays a crucial role in shaping our understanding of the natural world and driving progress in the field of biomedicine.Generated from the website